

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

	<u>June 30, 2013</u>	<u>December 31, 2012</u>
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 13,094	\$ 16,374
Restricted cash	99	96
Short-term bank deposits	15,015	3,215
Investment in Evogene	4,713	5,196
Other accounts receivable and prepaid expenses	736	690
<u>Total current assets</u>	<u>33,657</u>	<u>25,571</u>
NON- CURRENT INVESTMENTS:		
Long-term lease deposits	22	59
Severance pay fund	1,900	1,728
<u>Total non- current investments</u>	<u>1,922</u>	<u>1,787</u>
LONG-TERM PREPAID EXPENSES	201	301
PROPERTY AND EQUIPMENT, NET	1,226	1,250
<u>Total assets</u>	<u>\$ 37,006</u>	<u>\$ 28,909</u>

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except share and per share data)

	<u>June 30, 2013</u>	<u>December 31, 2012</u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Trade payables	\$ 857	\$ 443
Other accounts payable and accrued expenses	<u>1,219</u>	<u>941</u>
<u>Total</u> current liabilities	<u>2,076</u>	<u>1,384</u>
NON-CURRENT LIABILITIES:		
Research and development funding arrangements and others	12,037	7,872
Accrued severance pay	<u>2,179</u>	<u>1,981</u>
<u>Total</u> non-current liabilities	<u>14,216</u>	<u>9,853</u>
COMMITMENTS AND CONTINGENT LIABILITIES		
SHAREHOLDERS' EQUITY:		
Share capital:		
Ordinary shares of NIS 0.01 par value: 100,000,000 shares authorized at June 30, 2013 and December 31, 2012; 38,361,450 and 36,590,478 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively	104	99
Additional paid-in capital	216,304	206,325
Accumulated other comprehensive income	4,838	5,367
Accumulated deficit	<u>(200,532)</u>	<u>(194,119)</u>
<u>Total</u> shareholders' equity	<u>20,714</u>	<u>17,672</u>
<u>Total</u> liabilities and shareholders' equity	<u>\$ 37,006</u>	<u>\$ 28,909</u>

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

U.S. dollars in thousands (except share and per share data)

	Six months ended	
	June 30,	
	2013	2012
		Unaudited
Revenues	\$ 184	-
Cost of revenues	234	-
Gross loss	(50)	-
Operating expenses:		
Research and development expenses, net	6,176	4,047
Marketing and business development expenses	352	351
General and administrative expenses	2,105	1,679
<u>Total operating expenses</u>	<u>8,633</u>	<u>6,077</u>
Operating loss	(8,683)	(6,077)
Financial income, net	2,270	1,332
Net loss	<u>\$ (6,413)</u>	<u>\$ (4,745)</u>
Basic net loss per share	<u>\$ (0.17)</u>	<u>\$ (0.13)</u>
Weighted average number of Ordinary shares used in computing basic net loss per share	<u>37,746,520</u>	<u>35,628,390</u>
Diluted net loss per share	<u>\$ (0.18)</u>	<u>\$ (0.13)</u>
Weighted average number of Ordinary shares used in computing diluted net loss per share	<u>39,140,651</u>	<u>35,628,390</u>